| Macular edema due to diabetes mellitus
Beovu vs Eylea HD
Side-by-side clinical, coverage, and cost comparison for macular edema due to diabetes mellitus.Deep comparison between: Beovu vs Eylea Hd with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsEylea Hd has a higher rate of injection site reactions vs Beovu based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Eylea Hd but not Beovu, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Beovu
Eylea Hd
At A Glance
Intravitreal injection
Every 8-12 weeks (maintenance)
VEGF-A inhibitor
Intravitreal injection
Every 8-16 weeks
VEGF-A/PlGF inhibitor
Indications
- Exudative age-related macular degeneration
- Macular edema due to diabetes mellitus
- Age related macular degeneration
- Macular edema due to diabetes mellitus
- Diabetic Retinopathy
- Retinal Vein Occlusion
Dosing
Exudative age-related macular degeneration 6 mg (0.05 mL) by intravitreal injection monthly (every 25-31 days) for first 3 doses, followed by 6 mg every 8-12 weeks.
Macular edema due to diabetes mellitus 6 mg (0.05 mL) by intravitreal injection every 6 weeks (every 39-45 days) for first 5 doses, followed by 6 mg every 8-12 weeks.
Age related macular degeneration, Macular edema due to diabetes mellitus 8 mg (0.07 mL) intravitreal injection every 4 weeks for 3 doses, then once every 8 to 16 weeks (+/- 1 week); extended dosing once every 20 weeks (+/- 1 week) may be considered after 1 year of successful response.
Diabetic Retinopathy 8 mg (0.07 mL) intravitreal injection every 4 weeks for 3 doses, then once every 8 to 12 weeks (+/- 1 week).
Retinal Vein Occlusion 8 mg (0.07 mL) intravitreal injection every 4 weeks for 3 to 5 doses, then once every 8 weeks (+/- 1 week).
Contraindications
- Ocular or periocular infections
- Active intraocular inflammation
- Known hypersensitivity to brolucizumab or any excipient in BEOVU
- Ocular or periocular infections
- Active intraocular inflammation
- Known hypersensitivity to aflibercept or any excipient in EYLEA HD
Adverse Reactions
Most common (>=1%) Vision blurred, cataract, conjunctival hemorrhage, vitreous floaters, eye pain, intraocular inflammation, intraocular pressure increased, retinal hemorrhage, vitreous detachment, conjunctivitis, retinal pigment epithelial tear, corneal abrasion, hypersensitivity, punctate keratitis, retinal tear, endophthalmitis, blindness, retinal artery occlusion, retinal detachment, conjunctival hyperemia, lacrimation increased, abnormal sensation in eye, detachment of retinal pigment epithelium, vitreous hemorrhage
Serious Endophthalmitis, retinal detachment, retinal vasculitis, retinal vascular occlusion, intraocular pressure increase, thromboembolic events, hypersensitivity
Most common (>=3%) Cataract, conjunctival hemorrhage, corneal epithelium defect, intraocular pressure increased, ocular discomfort/eye pain/eye irritation, retinal hemorrhage, vision blurred, vitreous detachment, vitreous floaters
Serious Endophthalmitis, retinal detachments, retinal vasculitis with or without occlusion, increase in intraocular pressure, thromboembolic events
Postmarketing Retinal vasculitis, occlusive retinal vasculitis, scleritis
Pharmacology
VEGF-A inhibitor; brolucizumab is a humanized monoclonal single-chain Fv (scFv) antibody fragment that binds the three major isoforms of VEGF-A (VEGF110, VEGF121, VEGF165), blocking VEGFR-1 and VEGFR-2 interaction to suppress endothelial cell proliferation, neovascularization, and vascular permeability.
Aflibercept acts as a soluble decoy receptor that binds VEGF-A and PlGF, inhibiting their binding and activation of VEGFR-1 and VEGFR-2, thereby suppressing neovascularization and vascular permeability in the eye.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Beovu
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (0/12)
Eylea Hd
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Beovu
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Eylea Hd
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Beovu
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Eylea Hd
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Inherited Retinal Diseases - Public Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Inherited Retinal Diseases - Public Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Eylea HdView full Eylea Hd profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.